Highly competent in treating Adults and Children at an Advanced Level and is an Independent Nurse Prescriber.
A 2018 study found 5-amino-1MQ increased NAD+ by up to 40% in cultured adipocytes, but this cellular change precedes noticeable effects by weeks
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
Hsieh, M., Lee, C., Chueh, H., Chang, G., Huang, H., Lin, Y., & Pang, J
This aggressive initial dosing aims to saturate tissues rapidly, establishing therapeutic concentrations throughout the body
